Yiou Health learned on February 20 that Suzhou Aiyi Animal Pharmaceuticals (hereinafter referred to as "Aiyi Animal Pharmaceuticals") successfully completed the C round of financing with an amount of hundreds of millions of yuan.
This round of equity financing was jointly led by Yuanxi Haihe** and Songqing Shenhui Jiarui**, followed by Guohai Innovation Capital, Star Capital, and GSR United Capital Runpu**, and Su Gaoxin Rongsheng continued to make additional investments as an old shareholder. In addition to the equity part, this round of financing also further replenishes the company's long-term capital through 10-year debt financing. CEC Capital acted as exclusive financial advisor in connection with the transaction.
Aiyi Animal Pharmaceuticals is a leading pet vaccine company in China, committed to the research and development, registration and production of world-class quality pet vaccines, to solve the long-term shortage of varieties and strains in the domestic pet vaccine market, its product pipeline covers the lack of important varieties of pet vaccines in China, global innovative vaccines for the Chinese and international markets, as well as domestic replacement and upgrade products of existing imported pet vaccines.
Dr. Zhu Xianzhu, the founder and president of the company, has served as the executive vice president, chief scientific officer, chief biological product officer, and global R&D head of multinational companies such as Fudao Animal Health, Pfizer Animal Health (now Zoetis), Eli Lilly Animal Health, and Shihua Animal Health. To date, Aiyi Animal Pharmaceuticals has received five rounds of financing, including a number of US dollar and RMB private equity investments**, industrial capital and local guidance** investment and support.
The most advanced product in the research and development of animal drugs is the canine bronchial septic Brucella vaccine, also commonly known as kennel cough vaccine, kennel cough vaccine, BB vaccine, which is an important dog pet vaccine in the world, used to prevent cough, asthma and other respiratory diseases caused by bronchial septicaemia infection in dogs, as well as severe disease and death. Bordetella bronchiseptica, Bb), Bacillus pertussis, a gram-negative bacilli, is one of the main pathogens causing canine infectious respiratory disease (CIRD), i.e., kennel cough. Borcella canis bronchiseptic not only causes upper respiratory tract infections in dogs, but also increases the risk of other secondary respiratory tract infections and co-infections. Borcella canine bronchial septic causes health and life threats to pet dogs, and brings trouble and impact to pet families.
In developed countries in Europe and the United States, vaccination against kennel cough has become a common practice for pets. In addition to regular vaccination, dogs are required to be vaccinated against kennel cough for prevention or booster immunization when entering high-risk places for Borghebacter bronchial septicaemia infection such as pet hospitals, foster care, hotels, and grooming. The use of kennel cough vaccine in Europe and the United States is very large, with an annual sales volume of tens of millions of doses in the U.S. market, and large multinational companies such as Zoetis Company, Merck Animal Protection, Eli Lilly Animal Protection, and Boehringer Ingelheim Animal Health have registered and marketed Kennel cough vaccine in Europe and the United States. At present, there is no similar product on the market in China, Aiyi Animal Medicine has developed a nasal drop dosage form of canine kennel cough vaccine based on the technical route of mucosal immunity based on the prevalent strains in China, which can complete immunization with nasal drops once, which is also recognized by the international veterinary community as the most convenient and most protective dosage form.
Liu Ming, partner of Yuanxi Haihe**, said: "Based on its industrial resources in the field of vaccines, Yuanxi Haihe** has an in-depth understanding and technical judgment in the field of vaccines and biological products. The management team of Aiyi has long-term R&D and management experience in multinational enterprises. Through in-depth contact and evaluation of Aiyi Animal Medicine, we see that its R&D strength, team experience, production technology and quality system have reached the highest international standards, and we believe that Aiyi Animal Medicine will achieve great success in the field of pet vaccines and grow into the most international animal health enterprise in China. ”
Du Jiaying, investment director of Songqing Shenhui Jiarui**, said: "China's pet economy is in a stage of rapid development, compared with developed countries in Europe and the United States, China's pet medical market has huge growth space and potential. However, as the category with the highest R&D threshold and the highest added value in the field of pet medicine, the main market share of pet vaccines is occupied by imported brands, and the research and development of Aiyi animal drugs will bring more products and better choices to the pet vaccine market. We look forward to the launch of the pet vaccines under development in the near future, which will bring more products with good efficacy and safety to control dog and cat diseases and improve the health level of pets. ”
Zou Ruihang, Vice President of CEC Capital, said: "With the world's most advanced R&D team and the most complete pipeline layout in the field of pet vaccines, Aiyi Animal Pharmaceuticals is in a stage of rapid growth. This Series C financing has helped the company to supplement considerable long-term capital, which will surely drive the company to develop faster and better. In the recent capital market environment, we are pleased to be able to assist the best companies in the industry to complete their financing, and we are grateful to all investors for their attention and support to Aiyi Animal Pharmaceuticals. ”
Introduction:
Yuanxi Haihe** is a joint venture between CanSino Biologics and GSR United Capital, aiming to jointly build and maintain a biomedical ecosystem with innovation and synergy, take root in the industry and serve the industry, and promote the coordinated development of capital and industry with a win-win attitude. By integrating the rich industrial resources and professional investment management experience of CanSino Biologics and GSR United Capital, we believe that this cooperation will bring more opportunities and innovations to the biomedical industry, promote the progress of medical technology, and contribute to the cause of human health."
Songqing Shenhui Jiarui** was initiated and established by the service supporting Shanghai science and technology key project "G60 Brain Intelligence Science and Technology Innovation Base", which combines the business model of science base with the best technology, unites domestic institutes, and focuses on the "neck" technology of the science and technology industry, and carries out the incubation, transformation and industrialization of the science and technology industry through investment in the research and development of cutting-edge technologies.
Guohai Innovation Capital is a private equity management subsidiary of Guohai ** (000750), with a registered capital of 2 billion yuan and assets under management of more than 20 billion yuan. Focusing on scientific and technological innovation and healthy life, the investment areas cover medical care, new energy, new materials, and manufacturing. Committed to value investment, providing a full range of services to help enterprises grow, and create stable returns for investors.
Star Capital focuses on equity investment in the field of medicine and health, has deep industry insight and rich industrial resources, and has invested in many outstanding companies in innovative drugs, innovative medical devices, biotechnology, digital health and other subdivisions. With the mission of benefiting patients, Star Capital is determined to deepen the industry, accompany scientists and entrepreneurs to grow, and return investors with excellent performance.